PMV
PMV Do and dare company
mute

PMV is a do and dare company that is shaping the future of the Flemish economy.

PMV provides finance for promising businesses, from their very start, through their various growth stages and even on to operating internationally.

Working with and for the government and other partners, PMV implements projects that are important for prosperity and wellbeing in Flanders.

PMV coordinates the investment funds of the European Fund for Strategic Investments (EFSI) in Flanders

PMV is the contact point for every enquire for the Juncker Plan, officially the "European Fund for Strategic Investments" (EFSI).

More info

News

04
/10

Participation by Capricorn Venture Partners completes series A funding of PMV-portfolio company ViroVet

ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has attracted Capricorn Venture Partners to conclude the second closing of its series A financing round, raising another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.

portfolio

Key Technology

Key Technology
Testimonial: 
Key Technology is wereldleider op het vlak van machines voor de voedselverwerking. Zij bieden hierbij verschillende klantspecifieke oplossingen aan voor de behandeling, verwerking en verpakking van producten.

Awingu

Awingu
Testimonial: 
Awingu is een webbased platform waarmee de gebruiker toegang heeft tot al zijn bestanden, toepassingen en software, en dat van op het even welk apparaat, OS of browser.

Formac

Formac Pharmaceuticals
Testimonial: 
Formac is een spin-off van de Universiteit Leuven die zich focust op de formulering van slechte wateroplosbare geneesmiddelen.

Apitope

Apitope
Testimonial: 
Apitope is een Europees biotechbedrijf gericht op het onderzoek en ontwikkeling van revolutionaire ziektetherapie├źn voor auto-immuunziekten en allergie├źn, zoals multiple sclerose, de ziekte van Graves en Factor VIII.